Company intelligence / Profile preview

EndoLogic

Lodi, New Jersey, United States

Ownership: Private
Development stage: Other

Overview

EndoLogic develops pharmaceutical and endoscopic device technologies and has acquired worldwide rights to the small molecule renzapride (ATL-1251), a serotonin 5-HT4 receptor agonist and 5-HT3 receptor antagonist being developed primarily for diabetic gastroparesis and other gastrointestinal motility disorders, with prior clinical studies involving more than 5,000 patients and a Thorough QT study indicating no significant cardiac safety issues.[1][2]

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small moleculeBiologicDevice
Industry: Biotech

Beyond the preview

Go deeper on EndoLogic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EndoLogic.

Explore the full profile